This research reveals phlorizin's ability to inhibit excitotoxicity and improve neuroprotection in a rat model, indicating potential therapeutic effects.
This research investigates how phlorizin, a plant-derived dihydrochalcone, modulates glutamate release in synaptosomes and exerts neuroprotective effects in a rat model of kainic acid (KA)-induced excitotoxicity. In rat cortical synaptosomes, phlorizin concentration-dependently inhibited evoked glutamate release (IC₅₀ = 14.4 μM). This effect was abolished under calcium-free conditions or by blockade of P/Q type but not N type Ca²⁺ channels. In vivo, oral phlorizin pretreatment (100 mg/kg/day, 7 days) attenuated KA-induced seizures and neurodegeneration, restored NeuN and GAP-43 expression, and normalized cortical glutamate homeostasis by regulating GLT-1, glutamine synthetase, SNAT1/3, glutaminase, and VGLUT1. It shifted NMDA receptor subunit composition toward a neuroprotective profile (increasing GluN2A/GluN2B ratio) and suppressed astrocytic IL-1β/IL-1R1/Src signaling. Furthermore, phlorizin preserved blood brain barrier integrity by increasing ZO-1 and reducing albumin extravasation and MMP-9. These results demonstrate that phlorizin exerts multifaceted neuroprotection by inhibiting synaptic glutamate release, modulating glutamate homeostasis, and suppressing neuroinflammation and barrier disruption.
No takes yet. Share an insight, caveat, or question.
Lü et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: